liver-targeted allergen immunotherapy

Liver-targeted allergen immunotherapy (LIT) is an experimental allergen immunotherapy platform designed to rapidly and safely induce antigen-specific tolerance for the treatment of allergic diseases, such as allergic asthma and food allergies. Developed by researchers at the University of Chicago and New York University, with funding from Kanyos Bio (a subsidiary of Anokion), LIT utilizes synthetic mannosylation of native allergens to target them directly to the liver. This liver-targeted delivery prevents antibody-mediated recognition and subsequent anaphylaxis, while protein engineering prevents sensitization events caused by the proteolytic activity of native allergens. In preclinical models, LIT has been shown to induce allergen-specific regulatory T (Treg) cells, providing rapid and long-term control of allergic symptoms.

Other names

LITliver-targeted immunotherapy